BMS-986165

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

6 competitors in Systemic Lupus Erythematosus (SLE)

#DrugCompanyPhaseTrials

1

SG301

HHangzhou Sumgen Biotech Co., Ltd.

Phase 2

22

BMS-986165

Bristol-Myers Squibb

Phase 3

13

ESG206

SShanghai Escugen Biotechnology Co., Ltd

Phase 2

14

Cizutamig

CCandid Therapeutics

Phase 1

15

SAR448501

Sanofi

Phase 1

16

VIS171

Otsuka

Phase 1

1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Psoriasis8 trials

Safety Study of BMS-986165 in Healthy Subjects and to Treat Psoriasis

Completed·Bristol-Myers Squibb·Phase 1·NCT02534636·140 enrolled

A Clinical Study to Evaluate the Efficacy and Safety of D-2570 in the Treatment of Moderate to Severe Plaque Psoriasis.

Not yet recruiting·IInventisBio Co., Ltd·Phase 3·NCT07326813·477 enrolled

Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe Psoriasis

Completed·Bristol-Myers Squibb·Phase 2·NCT02931838·268 enrolled

Show 5 more trials

An Investigational Study to Evaluate Experimental Medication BMS-986165 in Japanese Participants With Moderate-to-Severe Psoriasis

Completed·Bristol-Myers Squibb·Phase 3·NCT03924427·74 enrolled

An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo in Participants With Plaque Psoriasis (POETYK-PSO-3) in Mainland China, Taiwan, and South Korea

Completed·Bristol-Myers Squibb·Phase 3·NCT04167462·220 enrolled

Effectiveness and Safety of BMS-986165 Compared to Placebo and Active Comparator in Participants With Psoriasis

Completed·Bristol-Myers Squibb·Phase 3·NCT03624127·666 enrolled

An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate-to-Severe Plaque Psoriasis

Completed·Bristol-Myers Squibb·Phase 3·NCT03611751·1,020 enrolled

An Open-Label, Multi-Center Extension Study to Characterize the Long-Term Safety and Efficacy of BMS-986165 in Subjects With Moderate-to-Severe Plaque Psoriasis

Completed·Bristol-Myers Squibb·Phase 3·NCT04036435·1,466 enrolled

Experimental5 trials

An Investigational Study of Experimental Medication BMS-986165 in Healthy Participants

Completed·Bristol-Myers Squibb·Phase 1·NCT03660436·131 enrolled

An Investigational Study to Evaluate Experimental Medication BMS-986165 Given as a Tablet and Solution in Healthy Male Participants

Completed·Bristol-Myers Squibb·Phase 1·NCT03739788·8 enrolled

An Investigational Study of Cyclosporine on Experimental Medication BMS-986165 in Healthy Male Participants

Completed·Bristol-Myers Squibb·Phase 1·NCT03419910·54 enrolled

Show 2 more trials

An Investigational Study of Experimental Medication BMS-986165 in Healthy Participants to Study Electrocardiogram Effects

Completed·Bristol-Myers Squibb·Phase 1·NCT03541564·84 enrolled

Assessment of Gut Absorption of Experimental Medication BMS-986165 in Healthy Males

Completed·Bristol-Myers Squibb·Phase 1·NCT03873415·9 enrolled

Ulcerative Colitis2 trials

Safety and Efficacy of Deucravacitinib in Participants With Moderate to Severe Ulcerative Colitis

Completed·Bristol-Myers Squibb·Phase 2·NCT03934216·131 enrolled

A Study of the Safety, Efficacy, and Biomarker Response of BMS-986165 in Participants With Moderate to Severe Ulcerative Colitis

Completed·Bristol-Myers Squibb·Phase 2·NCT04613518·38 enrolled

ART2 trials

The Effects Diflunisal on the Levels of BMS-986165 in Healthy Participants

Completed·Bristol-Myers Squibb·Phase 1·NCT04113668·48 enrolled

A Taste Assessment of BMS-986165 in Healthy Participants

Completed·Bristol-Myers Squibb·Phase 1·NCT03751228·9 enrolled

Systemic Lupus Erythematosus2 trials

Long-Term Safety and Efficacy Study of Deucravacitinib in Participants With Systemic Lupus Erythematosus

Completed·Bristol-Myers Squibb·Phase 2·NCT03920267·261 enrolled

An Investigational Study to Evaluate BMS-986165 in Participants With Systemic Lupus Erythematosus

Completed·Bristol-Myers Squibb·Phase 2·NCT03252587·363 enrolled

21 more indications

Drug2 trials

An Investigational Study to Determine the Drug Level Profile of BMS-986165 in Healthy Male Volunteers Following Transporter Inhibition.

Completed·Bristol-Myers Squibb·Phase 1·NCT04086719·16 enrolled

A Study to Investigate the Effects of Cytochrome P450 1A2 Induction by Ritonavir on BMS-986165 Drug Levels and Effects in Healthy Participants

Completed·Bristol-Myers Squibb·Phase 1·NCT04055506·16 enrolled

Metformin1 trial

Effect of BMS-986165 on the Blood Levels of Metformin

Completed·Bristol-Myers Squibb·Phase 1·NCT04671953·36 enrolled

Moderate to Severe Crohn's Disease1 trial

An Investigational Study of Experimental Medication BMS-986165 in Participants With Moderate to Severe Crohn's Disease

Terminated·Bristol-Myers Squibb·Phase 2·NCT03599622·239 enrolled

Female1 trial

The Effect of BMS-986165 Combined With an Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female Patients

Completed·Bristol-Myers Squibb·Phase 1·NCT03262727·49 enrolled

Gastric Acid1 trial

A Study to Investigate the Effects of Gastric Acid Suppression by Rabeprazole and BMS-986165 on How Fast and Complete The Drug is Absorbed Into the Body of Healthy Participants

Completed·Bristol-Myers Squibb·Phase 1·NCT03979248·21 enrolled

Kidney Disease1 trial

A Study to Assess the Safety of Experimental Medication BMS986165 in Participants With Normal Kidney Function and Participants With Mild to End-Stage Kidney Disease.

Completed·Bristol-Myers Squibb·Phase 1·NCT03890770·44 enrolled

Treatment1 trial

A Study Comparing the Effects of Famotidine Pretreatment and of Food on the Relative Bioavailability of BMS-986165 in Healthy Volunteers

Completed·Bristol-Myers Squibb·Phase 1·NCT04209699·18 enrolled

Tics1 trial

Pharmacokinetics (Drug Levels in Blood) of BMS-986165 When Taken as Various Solid Tablet Prototypes by Healthy Participants

Completed·Bristol-Myers Squibb·Phase 1·NCT04249284·18 enrolled

Methotrexate1 trial

A Study to Investigate BMS-986165 and Methotrexate in Healthy Male Patients

Completed·Bristol-Myers Squibb·Phase 1·NCT03402087·30 enrolled

Metabolism1 trial

Pharmacokinetics and Metabolism of [14C]BMS-986165 in Healthy Male Participants

Completed·Bristol-Myers Squibb·Phase 1·NCT03004768·6 enrolled

Double-blind1 trial

Single and Multiple Dose Pharmacokinetics of BMS-986165 in a Randomized, Double-Blind, Placebo-Controlled Study in Healthy Chinese Subjects

Completed·Bristol-Myers Squibb·Phase 1·NCT03956953·135 enrolled

Function1 trial

An Investigational Study of BMS-986165 in Participants With Normal Liver Function and Participants With Mild to Severe Liver Damage

Completed·Bristol-Myers Squibb·Phase 1·NCT03890809·32 enrolled

Gastric1 trial

A Study to Evaluate BMS-986165 Tablet Formulation Relative to BMS-986165 Capsule Formulation and the Effect of a High-Fat/ High-Calorie Meal and Increased Gastric pH on the BMS-986165 Tablet Formulation

Completed·Bristol-Myers Squibb·Phase 1·NCT03254784·49 enrolled

Systemic1 trial

Study to Characterize the Effects of Cytochrome p450 1A2 Inhibition on Systemic Exposure to BMS-986165

Completed·Bristol-Myers Squibb·Phase 1·NCT03930602·16 enrolled

Statin1 trial

Effect of BMS-986165 on the Pharmacokinetics of Rosuvastatin

Completed·Bristol-Myers Squibb·Phase 1·NCT03044873·20 enrolled

Adult1 trial

A Study to Compare the Taste and Levels in Blood Plasma of BMS-986165 When Taken as Different Formulations by Healthy Adult Participants

Completed·Bristol-Myers Squibb·Phase 1·NCT04305899·40 enrolled

Psoriatic Arthritis1 trial

Efficacy and Safety of BMS-986165 Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA)

Completed·Bristol-Myers Squibb·Phase 2·NCT03881059·203 enrolled

Lupus Nephritis1 trial

An Investigational Study to Evaluate the Safety and Effectiveness of BMS-986165 With Background Treatment in Participants With Lupus Nephritis

Terminated·Bristol-Myers Squibb·Phase 2·NCT03943147·16 enrolled

Prostate Cancer1 trial

A Phase 2 Study of Androgen Deprivation Therapy and BMS986365 in High-Risk Localized Prostate Cancer Patients Prior to Radical Prostatectomy

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT07335796·7 enrolled

Systemic Lupus Erythematosus (SLE)1 trial

A Continuation Protocol for Deucravacitinib in Patients With Patients With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132

Recruiting·Bristol-Myers Squibb·Approved·NCT06875960·35 enrolled

Unspecified1 trial

A Study to Determine the Pharmacokinetic Profile of BMS-986165 Tablets

Completed·Bristol-Myers Squibb·Phase 1·NCT04065932·33 enrolled

Details

Drug Info

Related News